1. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998. 41:1241–1248.
Article
2. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care. 2002. 5:551–559.
Article
3. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003. 112:1821–1830.
Article
4. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003. 112:1796–1808.
Article
5. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 1997. 389:610–614.
Article
6. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004. 114:147–152.
Article
7. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature. 2001. 409:307–312.
Article
8. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005. 436:356–362.
Article
9. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010. 72:219–246.
Article
10. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004. 24:29–33.
Article
11. Hausman DB, DiGirolamo M, Bartness TJ, Hausman GJ, Martin RJ. The biology of white adipocyte proliferation. Obes Rev. 2001. 2:239–254.
Article
12. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993. 259:87–91.
Article
13. Wang P, Mariman E, Renes J, Keijer J. The secretory function of adipocytes in the physiology of white adipose tissue. J Cell Physiol. 2008. 216:3–13.
Article
14. Josep BR, Amir G, Jennifer K, Raquel H. Peroxisome proliferator-activated receptors: the nutritionally controlled molecular networks that integrate inflammation, immunity and metabolism. Curr Nutr Food Sci. 2005. 1:179–187.
Article
15. Capasso F, Borrelli F, Capasso R, Di Carlo G, Izzo A, Pinto L, Mascolo N, Castaldo S, Longo R. Aloe and its therapeutic use. Phytother Res. 1998. 12:S124–S127.
Article
16. Heggers JP, Kucukcelebi A, Stabenau CJ, Ko F, Broemeling LD, Robson MC, Winters WD. Wound healing effects of Aloe gel and other topical antibacterial agents on rat skin. Phytother Res. 1995. 9:455–457.
Article
17. Koo MWL. Aloe vera: Antiulcer and antidiabetic effects. Phytother Res. 1994. 8:461–464.
Article
18. Winters WD, Benavides R, Clouse WJ. Effects of aloe extracts on human normal and tumor cells in vitro. Econ Bot. 1981. 35:89–95.
Article
19. Yongchaiyudha S, Rungpitarangsi V, Bunyapraphatsara N, Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L. juice: I. Clinical trial in new cases of diabetes mellitus. Phytomedicine. 1996. 3:241–243.
Article
20. Bunyapraphatsara N, Yongchaiyudha S, Rungpitarangsi V, Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L. juice. II. Clinical trial in diabetes mellitus patients in combination with glibenclamide. Phytomedicine. 1996. 3:245–248.
Article
21. Schwarz K, Mertz W. Chromium(III) and the glucose tolerance factor. Arch Biochem Biophys. 1959. 85:292–295.
Article
22. Anderson RA. Chromium, glucose intolerance and diabetes. J Am Coll Nutr. 1998. 17:548–555.
Article
23. Kim K, Kim H, Kwon J, Lee S, Kong H, Im SA, Lee YH, Lee YR, Oh ST, Jo TH, Park YI, Lee CK, Kim K. Hypoglycemic and hypolipidemic effects of processed Aloe vera gel in a mouse model of non-insulin-dependent diabetes mellitus. Phytomedicine. 2009. 16:856–863.
Article
24. Kong H, Lee S, Shin S, Kwon J, Jo TH, Shin E, Shim KS, Park YI, Lee CK, Kim K. Down-regulation of adipogenesis and hyperglycemia in diet-induced obesity mouse model by Aloe QDM. Biomolecules Therapeutics. 2010. 18:336–342.
Article
25. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, Vats D, Morel CR, Goforth MH, Subramanian V, Mukundan L, Ferrante AW, Chawla A. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab. 2008. 7:496–507.
Article
26. Kim J, Temple KA, Jones SA, Meredith KN, Basko JL, Brady MJ. Differential modulation of 3T3-L1 adipogenesis mediated by 11beta-hydroxysteroid dehydrogenase-1 levels. J Biol Chem. 2007. 282:11038–11046.
Article
27. Kim JO, Kim KS, Lee GD, Kwon JH. Antihyperglycemic and antioxidative effects of new herbal formula in streptozotocin-induced diabetic rats. J Med Food. 2009. 12:728–735.
Article
28. Stienstra R, Mandard S, Tan NS, Wahli W, Trautwein C, Richardson TA, Lichtenauer-Kaligis E, Kersten S, Müller M. The Interleukin-1 receptor antagonist is a direct target gene of PPARalpha in liver. J Hepatol. 2007. 46:869–877.
Article
29. Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem. 2000. 275:28240–28245.
Article